RxDoctor Payments Data

Philip Latourette, MD

Pain Medicine · Greenwood, SCNPI 1578596995

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,450 of the $3,840 with a category attached, or 89.9%. 26 manufacturers reported payments, led by Medtronic at 31.3% of the total. Reporting peaked in 2024 at $969 and has fallen 59.7% since, to $391 in 2025.

$3,840in general payments, 2019–2025

Across 183 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Vertos Medical, Inc.$596
  • Nevro Corp.$535
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$335
  • Arbor Pharmaceuticals, Inc.$261
  • Scilex Pharmaceuticals Inc.$160
  • plus $750 from 20 others

What the payments were for

  • Travel & lodging$39010%
  • Food & beverage$3,45090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,840 in reported general payments places this provider in the 55th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$98,873
Medicare patients
237
Services billed
898

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,136$41,704
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen819$22,239
Naloxone Hcl209$13,574
Oxycodone Hcl191$3,057
Fentanyl24$2,384
Morphine Sulfate ErMorphine Sulfate87$2,299
Gabapentin110$2,120
Pregabalin75$1,523
Morphine Sulfate61$1,179
Tramadol Hcl68$906
Baclofen11$252
Tizanidine Hcl23$208
Methadone Hcl11$81
Zolpidem Tartrate12$63
Lorazepam15$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAMorphine Sulfate$14$1,17961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →